{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-25-001264","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.027037+00:00","generated_at":"2026-05-17T13:58:34.849620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance","bullets":["Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.","Net loss $17.0M vs $15.5M; diluted EPS $(0.15) vs $(0.17); Adjusted EBITDA $(4.1)M vs $(8.7)M.","Pharmacy revenue $62.6M with >$11M gross profit; over 40% YoY growth.","Expanding capitated partnership with Elevance into two new Florida counties (more than double lives) and with Silver Summit in Nevada.","Reaffirms full-year 2025 guidance; expects revenue at high end of range and positive Adjusted EBITDA by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-25-001264","json":"https://secwatch.observer/filing/0001079973-25-001264.json","markdown":"https://secwatch.observer/filing/0001079973-25-001264.md","text":"https://secwatch.observer/filing/0001079973-25-001264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001264/0001079973-25-001264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001264/toi_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:34.849620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}